

	Model Aa				Model Bb				Model Cc			
	HR (CI)	(95%)	P	FDR	HR (CI)	(95%)	P	FDR	HR (CI)	(95%)	P	FDR
Recurrence-free survival												
CD4 ⁺ Tcm												
WCH	1.45 (0.85–2.45)		0.17	0.662	1.51 (0.82–2.79)		0.187	0.798	1.68 (0.87–3.24)		0.122	0.625
TCGA	1.30 (1.01–1.66)		0.042	0.25	1.52 (1.14–2.02)		0.004	0.07	1.64 (1.21–2.22)		0.001	0.035
Meta-analysis	1.33 (1.06–1.66)		0.014	0.222	1.52 (1.17–1.97)		0.002	0.035	1.65 (1.25–2.17)		<0.001	0.009
<i>I</i> ² , <i>P</i> _{heterogeneity}	<i>I</i> ² = 0.0%, <i>P</i> = 0.714				<i>I</i> ² = 75.0%, <i>P</i> = 0.985				<i>I</i> ² = 75.0%, <i>P</i> = 0.948			
Plasma cells												
WCH	0.42 (0.20–0.91)		0.027	0.379	0.43 (0.20–0.89)		0.023	0.403	0.42 (0.20–0.90)		0.026	0.499
TCGA	0.47 (0.25–0.92)		0.027	0.245	0.37 (0.18–0.75)		0.006	0.07	0.34 (0.16–0.73)		0.006	0.093
Meta-analysis	0.45 (0.27–0.73)		0.001	0.035	0.40 (0.24–0.67)		<0.001	0.018	0.38 (0.22–0.65)		<0.001	0.009
<i>I</i> ² , <i>P</i> _{heterogeneity}	<i>I</i> ² = 0.0%, <i>P</i> = 0.825				<i>I</i> ² = 0.0%, <i>P</i> = 0.775				<i>I</i> ² = 0.0%, <i>P</i> = 0.698			
Overall survival												
Plasma cells												
WCH	0.18 (0.05–0.65)		0.009	0.245	0.19 (0.06–0.68)		0.01	0.35	0.20 (0.05–0.75)		0.017	0.595
TCGA	0.49 (0.25–0.98)		0.043	0.298	0.39 (0.18–0.81)		0.01	0.21	0.36 (0.16–0.80)		0.012	0.163
Meta-analysis	0.35 (0.14–0.88)		0.026	0.46	0.32 (0.17–0.61)		<0.001	0.018	0.31 (0.16–0.62)		0.001	0.035
<i>I</i> ² , <i>P</i> _{heterogeneity}	<i>I</i> ² = 45.2%, <i>P</i> = 0.177				<i>I</i> ² = 0.0%, <i>P</i> = 0.324				<i>I</i> ² = 0.0%, <i>P</i> = 0.465			